FDA Safety Review of Mifepristone Continues Into 2027
The FDA says its mifepristone safety review will continue into 2027, with a study expected to finish by mid-December and a report due no later than March. The agency says…
The FDA says its mifepristone safety review will continue into 2027, with a study expected to finish by mid-December and a report due no later than March. The agency says…
The FDA has granted Breakthrough Device Designation to Neuralink’s Blindsight, an experimental implant designed to restore vision by stimulating the visual cortex. The technology bypasses damaged eyes and optic nerves…
The Trump administration has successfully narrowed the FDA approval for the drug leucovorin, focusing on a rare genetic brain disorder. This move follows a rigorous review process that prioritized the…
The Trump administration has proposed a new FDA pathway to accelerate the approval of customized treatments for rare genetic diseases. This initiative, known as the plausible mechanism, allows for the…
Secretary Robert F. Kennedy Jr. is implementing a policy of radical transparency to rebuild trust in federal health agencies. The Department of Health and Human Services is streamlining data collection…
The Trump administration has successfully moved to regulate chest-compressing garments as medical devices through the Food and Drug Administration. Twelve companies have received formal warnings to stop marketing these products…